Abstract:Abstract Gene therapy presents a potentially transformational approach to haemophilia management. The patient journey for gene therapy is unlike that for other haemophilia treatments, and its one-time, irreversible nature has led to broad agreement that informed shared decision-making is essential. Understanding the educational and support needs of people with haemophilia (PwH) who may consider or undergo gene therapy in the future is key to enabling this. A one-day patient advisory board was conducted with the aim of gaining insights on what education and support would enable PwH to have appropriate conversations with health care practitioners (HCPs) about gene therapy and participate in informed shared decision-making. The participants were 11 age-diverse men with severe haemophilia A or B, including six who had received gene therapy in phase 1-3 clinical trials. Two were members of a national patient organisation or a patient organisation leader. Participants agreed that informed shared decision-making was essential for gene therapy, but most felt the choice to have gene therapy would be limited by healthcare budgets and access arrangements. They identified key education needed by PwH to enable true informed decision-making, best delivered through a collaborative approach by patient organisations and HCPs. Eligibility criteria should be more widely shared within the community as part of general education around gene therapy. Gene therapy should be presented as one of a range of treatment options; understanding its risks, uncertainties and benefits is key to managing expectations and minimising treatment remorse. Awareness of how different factor levels impact bleeding tendency and frequency would be helpful, as success of gene therapy cannot be determined by factor activity alone. Other key educational needs included follow-up commitments, the role and potential side effects of corticosteroids or other immunosuppressants, impact on sense of identity, mental health, family planning, and managing bleeds after gene therapy. Teach-back could help ensure appropriate levels of understanding; psychological support could aid managing expectations. Peer-to-peer learning delivered across a variety of platforms, to share experiences of gene therapy and contextualise more ‘formal’ gene therapy education, was considered invaluable.

Understanding patient and parent/caregiver perceptions on gene therapy in Gaucher disease: an international survey

Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry

Advancements in Viral Gene Therapy for Gaucher Disease

Perspectives of the Friedreich ataxia community on gene therapy clinical trials

An Overview of Gaucher Disease

A multinational survey of potential participant perspectives on ocular gene therapy

Insights, Achievements, and Lessons Learned from a Global Patient Registry

Different diseases, different needs: Patient preferences for gene therapy in lysosomal storage disorders, a probabilistic threshold technique survey

A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy

Gaucher Disease: A Glance from a Medicinal Chemistry Perspective

A natural history study of pediatric patients with early onset of GM1 gangliosidosis, GM2 gangliosidoses, or gaucher disease type 2 (RETRIEVE)

Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1

Genotypes and Phenotypes in 20 Chinese Patients with Type 2 Gaucher Disease

Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry

Survey of perspectives of people with inherited retinal diseases on ocular gene therapy in Australia

Gene therapy in sickle cell disease: Attitudes and informational needs of patients and caregivers

The natural history of Gaucher disease type 1 in 31 patients over a median of 15 years: a retrospective study

A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient advisory board

Qualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP)

Ethics, policy, and rare genetic disorders: the case of Gaucher disease in Israel

Clinician's perspectives on gene therapy for Alzheimer's disease: A qualitative study